RT Journal Article
T1 Aspirin Therapy on Prophylactic Anticoagulation for Patients Hospitalized With COVID-19: A Propensity Score-Matched Cohort Analysis of the HOPE-COVID-19 Registry.
A1 Santoro, Francesco
A1 Núñez-Gil, Ivan J
A1 Vitale, Enrica
A1 Viana-Llamas, María C
A1 Romero, Rodolfo
A1 Maroun Eid, Charbel
A1 Feltes Guzman, Gisela
A1 Becerra-Muñoz, Victor Manuel
A1 Fernández Rozas, Inmaculada
A1 Uribarri, Aitor
A1 Alfonso-Rodriguez, Emilio
A1 García Aguado, Marcos
A1 Huang, Jia
A1 Castro Mejía, Alex Fernando
A1 Garcia Prieto, Juan Fortunato
A1 Elola, Javier
A1 Ugo, Fabrizio
A1 Cerrato, Enrico
A1 Signes-Costa, Jaime
A1 Raposeiras Roubin, Sergio
A1 Jativa Mendez, Jorge Luis
A1 Espejo Paeres, Carolina
A1 López Masjuan, Alvaro
A1 Marin, Francisco
A1 Guerra, Federico
A1 El-Battrawy, Ibrahim
A1 Cortese, Bernardo
A1 Ramakrishna, Harish
A1 Perez-Villacastín, Julian
A1 Fernandez-Ortiz, Antonio
A1 Brunetti, Natale Daniele
K1 COVID‐19
K1 anticoagulation
K1 antiplatelet therapy
K1 aspirin
K1 prognosis
K1 risk prediction
AB Background COVID-19 is an infectious illness, featured by an increased risk of thromboembolism. However, no standard antithrombotic therapy is currently recommended for patients hospitalized with COVID-19. The aim of this study was to evaluate safety and efficacy of additional therapy with aspirin over prophylactic anticoagulation (PAC) in patients hospitalized with COVID-19 and its impact on survival. Methods and Results A total of 8168 patients hospitalized for COVID-19 were enrolled in a multicenter-international prospective registry (HOPE COVID-19). Clinical data and in-hospital complications, including mortality, were recorded. Study population included patients treated with PAC or with PAC and aspirin. A comparison of clinical outcomes between patients treated with PAC versus PAC and aspirin was performed using an adjusted analysis with propensity score matching. Of 7824 patients with complete data, 360 (4.6%) received PAC and aspirin and 2949 (37.6%) PAC. Propensity-score matching yielded 298 patients from each group. In the propensity score-matched population, cumulative incidence of in-hospital mortality was lower in patients treated with PAC and aspirin versus PAC (15% versus 21%, Log Rank P=0.01). At multivariable analysis in propensity matched population of patients with COVID-19, including age, sex, hypertension, diabetes, kidney failure, and invasive ventilation, aspirin treatment was associated with lower risk of in-hospital mortality (hazard ratio [HR], 0.62; [95% CI 0.42-0.92], P=0.018). Conclusions Combination PAC and aspirin was associated with lower mortality risk among patients hospitalized with COVID-19 in a propensity score matched population compared to PAC alone.
YR 2022
FD 2022-06-22
LK http://hdl.handle.net/10668/20200
UL http://hdl.handle.net/10668/20200
LA en
DS RISalud
RD Apr 11, 2025